Effect of Epicutaneous Immunotherapy Versus Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial

Purpose Of The Study: To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among children with peanut allergy. Study Population: The study included 356 children with peanut allergy aged 4 to 11 years without a history of severe peanut-related anaphylaxis who sh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatrics (Evanston) 2019-12, Vol.144 (Supplement_1), p.S34-S34
Hauptverfasser: Podgorski, Christopher A., Leo, Harvey
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S34
container_issue Supplement_1
container_start_page S34
container_title Pediatrics (Evanston)
container_volume 144
creator Podgorski, Christopher A.
Leo, Harvey
description Purpose Of The Study: To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among children with peanut allergy. Study Population: The study included 356 children with peanut allergy aged 4 to 11 years without a history of severe peanut-related anaphylaxis who showed objective signs and symptoms of reactivity at an eliciting dose of ≤300 mg of peanut protein during a double-blinded, placebo-controlled food challenge. Methods: This study was a phase 3, randomized, double-blinded, placebo-controlled multicenter trial. Study participants were stratified into low- (≤10 mg) and high-eliciting dose (10–300 mg) subgroups on the basis of participants' screening eliciting dose. Participants were then randomly assigned into groups receiving a daily epicutaneous patch containing 250 µg of peanut protein (n = 238) or a daily placebo patch (n = 118). Treatment response was defined as a posttreatment eliciting dose of ≥300 or ≥1000 mg of peanut protein for the pretreatment low- and high-eliciting dose subgroups, respectively. The treatment effect of the immunotherapy was determined by the response rate difference between the treatment and placebo groups after 12 months. A margin of 15% was selected as the lower bound of the 95% confidence interval (CI) for determining a positive trial result. The incidence of treatment-emergent adverse events (TEAEs) was also followed in each group. Results: After 12 months, the response rates of the treatment (35.3%) and placebo (13.6%) groups were compared, showing a difference of 21.7% that was statistically significant (P < .001). However, the resulting lower bound of the 95% CI was 12.4%, which did not achieve the pretrial 15% criterion for clinically relevant significance. The incidence of TEAEs was 95.4% in the treatment group and 89% in the placebo group, in which application site reactions were the most common TEAE observed in both groups. There were 4 TEAEs in 3 treatment group participants that were classified as moderate anaphylactic reactions, all cases were appropriately treated, and 2 of these participants permanently discontinued the study. Conclusions: This study demonstrated a statistically significant difference between response rates of the peanut patch and placebo patch groups on the basis of eliciting doses during food challenges before and after the 12-month trial period. The results could not be considered a positive trial because the lower bound of the 95% CI was not met.
doi_str_mv 10.1542/peds.2019-2461YY
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2326862863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2326862863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c181y-13cfdfc2c4f37f229868588a60cceff0adef0705f68df9ef2f52f41b2dccf63a3</originalsourceid><addsrcrecordid>eNo1kU1PwzAMhiMEEmNw5xiJcyFJP5Zxm6YCk5CoYIB2qrLU3oLapCTtYfwf_icdg5Mtv49sWQ8hl5xd8zQRNy1U4VowPo1EkvHV6oiMOJvKKBGT9JiMGIt5lDCWnpKzED4YY0k6ESPynSOC7qhDmrdG952y4PpAF03TW9dtwat2R9_Ah2FY1ErD2lFn6TMo3Zmh6RwtQNm-o4V3HRhLF3YD4TebNc5u6Hxr6sqDpe-m2_7Ds7oGv9nd0uUWaJEXi2X-Qp-VrVxjvqCi89pYo1VNl96o-pycoKoDXPzVMXm9y5fzh-jx6X4xnz1Gmku-i3issUItdILxBIWYykymUqqMaQ2ITFWAbMJSzGSFU0CBqcCEr0WlNWaxisfk6rC39e6zH74oP1zv7XCyFLHIZCZkFg8UO1DauxA8YNl60yi_Kzkr9zLKvYxyL6M8yIh_AIrEgYs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2326862863</pqid></control><display><type>article</type><title>Effect of Epicutaneous Immunotherapy Versus Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Podgorski, Christopher A. ; Leo, Harvey</creator><creatorcontrib>Podgorski, Christopher A. ; Leo, Harvey</creatorcontrib><description>Purpose Of The Study: To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among children with peanut allergy. Study Population: The study included 356 children with peanut allergy aged 4 to 11 years without a history of severe peanut-related anaphylaxis who showed objective signs and symptoms of reactivity at an eliciting dose of ≤300 mg of peanut protein during a double-blinded, placebo-controlled food challenge. Methods: This study was a phase 3, randomized, double-blinded, placebo-controlled multicenter trial. Study participants were stratified into low- (≤10 mg) and high-eliciting dose (10–300 mg) subgroups on the basis of participants' screening eliciting dose. Participants were then randomly assigned into groups receiving a daily epicutaneous patch containing 250 µg of peanut protein (n = 238) or a daily placebo patch (n = 118). Treatment response was defined as a posttreatment eliciting dose of ≥300 or ≥1000 mg of peanut protein for the pretreatment low- and high-eliciting dose subgroups, respectively. The treatment effect of the immunotherapy was determined by the response rate difference between the treatment and placebo groups after 12 months. A margin of 15% was selected as the lower bound of the 95% confidence interval (CI) for determining a positive trial result. The incidence of treatment-emergent adverse events (TEAEs) was also followed in each group. Results: After 12 months, the response rates of the treatment (35.3%) and placebo (13.6%) groups were compared, showing a difference of 21.7% that was statistically significant (P &lt; .001). However, the resulting lower bound of the 95% CI was 12.4%, which did not achieve the pretrial 15% criterion for clinically relevant significance. The incidence of TEAEs was 95.4% in the treatment group and 89% in the placebo group, in which application site reactions were the most common TEAE observed in both groups. There were 4 TEAEs in 3 treatment group participants that were classified as moderate anaphylactic reactions, all cases were appropriately treated, and 2 of these participants permanently discontinued the study. Conclusions: This study demonstrated a statistically significant difference between response rates of the peanut patch and placebo patch groups on the basis of eliciting doses during food challenges before and after the 12-month trial period. The results could not be considered a positive trial because the lower bound of the 95% CI was not met.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2019-2461YY</identifier><language>eng</language><publisher>Evanston: American Academy of Pediatrics</publisher><subject>Allergies ; Anaphylaxis ; Children ; Clinical trials ; Food allergies ; Immunotherapy ; Incidence ; Ingestion ; Lower bounds ; Pediatrics ; Population studies ; Proteins ; Statistical analysis</subject><ispartof>Pediatrics (Evanston), 2019-12, Vol.144 (Supplement_1), p.S34-S34</ispartof><rights>Copyright American Academy of Pediatrics Dec 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Podgorski, Christopher A.</creatorcontrib><creatorcontrib>Leo, Harvey</creatorcontrib><title>Effect of Epicutaneous Immunotherapy Versus Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial</title><title>Pediatrics (Evanston)</title><description>Purpose Of The Study: To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among children with peanut allergy. Study Population: The study included 356 children with peanut allergy aged 4 to 11 years without a history of severe peanut-related anaphylaxis who showed objective signs and symptoms of reactivity at an eliciting dose of ≤300 mg of peanut protein during a double-blinded, placebo-controlled food challenge. Methods: This study was a phase 3, randomized, double-blinded, placebo-controlled multicenter trial. Study participants were stratified into low- (≤10 mg) and high-eliciting dose (10–300 mg) subgroups on the basis of participants' screening eliciting dose. Participants were then randomly assigned into groups receiving a daily epicutaneous patch containing 250 µg of peanut protein (n = 238) or a daily placebo patch (n = 118). Treatment response was defined as a posttreatment eliciting dose of ≥300 or ≥1000 mg of peanut protein for the pretreatment low- and high-eliciting dose subgroups, respectively. The treatment effect of the immunotherapy was determined by the response rate difference between the treatment and placebo groups after 12 months. A margin of 15% was selected as the lower bound of the 95% confidence interval (CI) for determining a positive trial result. The incidence of treatment-emergent adverse events (TEAEs) was also followed in each group. Results: After 12 months, the response rates of the treatment (35.3%) and placebo (13.6%) groups were compared, showing a difference of 21.7% that was statistically significant (P &lt; .001). However, the resulting lower bound of the 95% CI was 12.4%, which did not achieve the pretrial 15% criterion for clinically relevant significance. The incidence of TEAEs was 95.4% in the treatment group and 89% in the placebo group, in which application site reactions were the most common TEAE observed in both groups. There were 4 TEAEs in 3 treatment group participants that were classified as moderate anaphylactic reactions, all cases were appropriately treated, and 2 of these participants permanently discontinued the study. Conclusions: This study demonstrated a statistically significant difference between response rates of the peanut patch and placebo patch groups on the basis of eliciting doses during food challenges before and after the 12-month trial period. The results could not be considered a positive trial because the lower bound of the 95% CI was not met.</description><subject>Allergies</subject><subject>Anaphylaxis</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Food allergies</subject><subject>Immunotherapy</subject><subject>Incidence</subject><subject>Ingestion</subject><subject>Lower bounds</subject><subject>Pediatrics</subject><subject>Population studies</subject><subject>Proteins</subject><subject>Statistical analysis</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo1kU1PwzAMhiMEEmNw5xiJcyFJP5Zxm6YCk5CoYIB2qrLU3oLapCTtYfwf_icdg5Mtv49sWQ8hl5xd8zQRNy1U4VowPo1EkvHV6oiMOJvKKBGT9JiMGIt5lDCWnpKzED4YY0k6ESPynSOC7qhDmrdG952y4PpAF03TW9dtwat2R9_Ah2FY1ErD2lFn6TMo3Zmh6RwtQNm-o4V3HRhLF3YD4TebNc5u6Hxr6sqDpe-m2_7Ds7oGv9nd0uUWaJEXi2X-Qp-VrVxjvqCi89pYo1VNl96o-pycoKoDXPzVMXm9y5fzh-jx6X4xnz1Gmku-i3issUItdILxBIWYykymUqqMaQ2ITFWAbMJSzGSFU0CBqcCEr0WlNWaxisfk6rC39e6zH74oP1zv7XCyFLHIZCZkFg8UO1DauxA8YNl60yi_Kzkr9zLKvYxyL6M8yIh_AIrEgYs</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Podgorski, Christopher A.</creator><creator>Leo, Harvey</creator><general>American Academy of Pediatrics</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope></search><sort><creationdate>20191201</creationdate><title>Effect of Epicutaneous Immunotherapy Versus Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial</title><author>Podgorski, Christopher A. ; Leo, Harvey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c181y-13cfdfc2c4f37f229868588a60cceff0adef0705f68df9ef2f52f41b2dccf63a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Allergies</topic><topic>Anaphylaxis</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Food allergies</topic><topic>Immunotherapy</topic><topic>Incidence</topic><topic>Ingestion</topic><topic>Lower bounds</topic><topic>Pediatrics</topic><topic>Population studies</topic><topic>Proteins</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Podgorski, Christopher A.</creatorcontrib><creatorcontrib>Leo, Harvey</creatorcontrib><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Podgorski, Christopher A.</au><au>Leo, Harvey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Epicutaneous Immunotherapy Versus Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial</atitle><jtitle>Pediatrics (Evanston)</jtitle><date>2019-12-01</date><risdate>2019</risdate><volume>144</volume><issue>Supplement_1</issue><spage>S34</spage><epage>S34</epage><pages>S34-S34</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><abstract>Purpose Of The Study: To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among children with peanut allergy. Study Population: The study included 356 children with peanut allergy aged 4 to 11 years without a history of severe peanut-related anaphylaxis who showed objective signs and symptoms of reactivity at an eliciting dose of ≤300 mg of peanut protein during a double-blinded, placebo-controlled food challenge. Methods: This study was a phase 3, randomized, double-blinded, placebo-controlled multicenter trial. Study participants were stratified into low- (≤10 mg) and high-eliciting dose (10–300 mg) subgroups on the basis of participants' screening eliciting dose. Participants were then randomly assigned into groups receiving a daily epicutaneous patch containing 250 µg of peanut protein (n = 238) or a daily placebo patch (n = 118). Treatment response was defined as a posttreatment eliciting dose of ≥300 or ≥1000 mg of peanut protein for the pretreatment low- and high-eliciting dose subgroups, respectively. The treatment effect of the immunotherapy was determined by the response rate difference between the treatment and placebo groups after 12 months. A margin of 15% was selected as the lower bound of the 95% confidence interval (CI) for determining a positive trial result. The incidence of treatment-emergent adverse events (TEAEs) was also followed in each group. Results: After 12 months, the response rates of the treatment (35.3%) and placebo (13.6%) groups were compared, showing a difference of 21.7% that was statistically significant (P &lt; .001). However, the resulting lower bound of the 95% CI was 12.4%, which did not achieve the pretrial 15% criterion for clinically relevant significance. The incidence of TEAEs was 95.4% in the treatment group and 89% in the placebo group, in which application site reactions were the most common TEAE observed in both groups. There were 4 TEAEs in 3 treatment group participants that were classified as moderate anaphylactic reactions, all cases were appropriately treated, and 2 of these participants permanently discontinued the study. Conclusions: This study demonstrated a statistically significant difference between response rates of the peanut patch and placebo patch groups on the basis of eliciting doses during food challenges before and after the 12-month trial period. The results could not be considered a positive trial because the lower bound of the 95% CI was not met.</abstract><cop>Evanston</cop><pub>American Academy of Pediatrics</pub><doi>10.1542/peds.2019-2461YY</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 2019-12, Vol.144 (Supplement_1), p.S34-S34
issn 0031-4005
1098-4275
language eng
recordid cdi_proquest_journals_2326862863
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Allergies
Anaphylaxis
Children
Clinical trials
Food allergies
Immunotherapy
Incidence
Ingestion
Lower bounds
Pediatrics
Population studies
Proteins
Statistical analysis
title Effect of Epicutaneous Immunotherapy Versus Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A44%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Epicutaneous%20Immunotherapy%20Versus%20Placebo%20on%20Reaction%20to%20Peanut%20Protein%20Ingestion%20Among%20Children%20With%20Peanut%20Allergy:%20The%20PEPITES%20Randomized%20Clinical%20Trial&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Podgorski,%20Christopher%20A.&rft.date=2019-12-01&rft.volume=144&rft.issue=Supplement_1&rft.spage=S34&rft.epage=S34&rft.pages=S34-S34&rft.issn=0031-4005&rft.eissn=1098-4275&rft_id=info:doi/10.1542/peds.2019-2461YY&rft_dat=%3Cproquest_cross%3E2326862863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2326862863&rft_id=info:pmid/&rfr_iscdi=true